R. Andres Floto is a Wellcome Trust Investigator and Professor of Respiratory Biology in the Molecular Immunity Unit of the University of Cambridge (based at the MRC Laboratory of Molecular Biology), Research Director of the Cambridge Centre for Lung Infection at Royal Papworth Hospital, and Director of the UK Cystic Fibrosis (CF) Innovation Hub. 

His basic research is focused on understanding how macrophages interact with bacteria, how bacteria evolve during chronic infection and transmission, and how forward and reverse genetics can be combined with fragment-based drug discovery to develop novel antibiotics and host-directed therapies.

His clinical research is centred around tackling chronic inflammation in CF and non-CF bronchiectasis, treating Nontuberculous Mycobacteria (NTM), and using graphical model-based machine learning to understand and predict pulmonary exacerbations in CF. 

Clinically he specialises in the management of Nontuberculous mycobacteria, Cystic Fibrosis, non-CF bronchiectasis, and recurrent chest infections
He co-chairs the British Thoracic Society NTM guidelines committee, the joint US CF Foundation-European CF Society (ECFS) NTM Guidelines Group, and the ECFS working group on NTM.

Specialist Interests

Cystic Fibrosis (CF)
Non-CF Bronchiectasis
Lung infection (TB, Non Tuberculous Mycobacteria (NTM) and Aspergillus)
Primary and Secondary Immunodeficiencies

Research Interests
  • Bacterial genetics and genomics
  • Antibiotic discovery
  • Innate immunity to bacteria  See Floto Lab for more details
  • Regulation of lung inflammation
  • Machine Learning in biology and medicine

Professional Positions
  • Professor of Respiratory Biology, University of CambridgeWellcome Trust Investigator
  • Group Leader, University Molecular Immunity Unit, MRC Laboratory of Molecular Biology
  • Research Director, Cambridge Centre for Lung Infection
  • Director, Cambridge Cystic Fibrosis Innovation Hub
  • Honorary Consultant physician, Royal Papworth Hospital
  • Honorary Consultant physician, Cambridge University Hospitals
  • Co-chair of the British Thoracic Society NTM Guidelines Committee
  • Co-chair US CF Foundation-European CF Society NTM Guidelines Group
  • Co-chair ECFS Working Group on NTM
Professional Membership

Member, European Respiratory Society
Member, American Thoracic Society
Member, Association of Physicians of Great Britain and Ireland
Fellow, Royal College of Physicians UK
Member, European CF Society

Education and Training

1991 BA University of Cambridge
1995 MA University of Cambridge
1997 PhD University of Cambridge
1997 MB BChir University of Cambridge
2000 MRCP London
2007 Completion of specialist respiratory training
2013 FRCP London

Selected Publications

Bryant JM, Grogono DM, Rodriguez-Rincon D, Everall I, Brown KP, Moreno P, Verma D, Emily Hill E, Drijkoningen J, Gilligan P, Esther CR, Noone PG, Giddings O, Bell SC, Thomson R, Wainwright CE, Coulter C, Pandey S, Wood ME, Stockwell RE, Ramsay KA, Sherrard LJ, Kidd TJ, Jabbour N, Johnson GR, Knibbs LD, Morawska L, Sly PD, Jones A, Bilton D, Laurenson I, Ruddy M, Bourke S, Bowler ICJW, Chapman SJ, Clayton A, Cullen M, Daniels T, Dempsey O, Denton M, Desai M, Drew RJ, Edenborough F, Evans J, Folb J, Humphrey H, Isalska B, Jensen-Fangel S, Jönsson B, Jones AM, Katzenstein TL, Lillebaek T, MacGregor G, Mayell S, Millar M, Modha D, Nash EF, O’Brien C, O’Brien D, Ohri C, Pao CS, Peckham D, Perrin F, Perry A, Pressler T, Prtak L, Qvist T, Robb A, Rodgers H, Schaffer K, Shafi N, van Ingen J, Walshaw M, Watson D, West N, Whitehouse J, Haworth CS, Harris SR, Ordway D, Parkhill J, Floto RA. (2016). Emergence and spread of a human- transmissible multidrug-resistant nontuberculous mycobacterium. Science 354: 751-757. 

Cader MZ, Boroviak K, Zhang Q, Assadi G, Kempster SL, Sewell GW, Saveljeva S, Ashcroft JW, Clare S, Mukhopadhyay S, Brown KP, Tschurtschenthaler M, Raine T, Doe B, Chilvers ER, Griffin JL, Kaneider NC, Floto RA, D'Amato M, Bradley A, Wakelam MJ, Dougan G, Kaser A. (2016). C13orf31 (FAMIN) is a central regulator of immunometabolic function. Nat Immunol. 17: 1046-56.

Viviani L, Harrison MJ, Zolin A, Haworth CS, Floto RA. (2016). Epidemiology of nontuberculous mycobacteria (NTM) amongst individuals with cystic fibrosis (CF). J. Cyst Fibros. pii: S1569-1993(16)30008-X.

Klionsky DJ….Floto RA et al. (2016). Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy 12: 1-222.

Floto RA, Olivier KN, Saiman L, Daley CL, Herrmann J-L, Nick JA, Noone PG, Bilton D, Corris P, Gibson RL, Hempstead SE, Koetz K, Sabadosa KA, Sermet-Gaudelus I, Smyth AR, van Ingen J, Wallace RJ, Winthrop KL, Marshall BC, Haworth CS (2015). Cystic Fibrosis Foundation and European Cystic Fibrosis Society Consensus Recommendations for the Management of Nontuberculous Mycobacteria in Individuals with Cystic Fibrosis. Executive Summary. Thorax 2016; 71:88-90. 

Floto RA, Olivier KN, Saiman L, Daley CL, Herrmann J-L, Nick JA, Noone PG, Bilton D, Corris P, Gibson RL, Hempstead SE, Koetz K, Sabadosa KA, Sermet-Gaudelus I, Smyth AR, van Ingen J, Wallace RJ, Winthrop KL, Marshall BC, Haworth CS (2015). Cystic Fibrosis Foundation and European Cystic Fibrosis Society Consensus Recommendations for the Management of Nontuberculous Mycobacteria in Individuals with Cystic Fibrosis. Thorax 2016; 71 Suppl 1: i1-i22

Crousilles A, Maunders E, Bartlett S, Fan C, Ukor EF, Abdelhamid Y, Baker Y, Floto A, Spring DR, Welch M. (2015) Which microbial factors really are important in Pseudomonas aeruginosa infections? Future Microbiol. 10, 1825-36. 

Panagea T, Pincus DH, Grogono D, Jones M, Bryant J, Parkhill J, Floto RA, Gilligan P (2015). Mycobacterium abscessus Complex Identification with Matrix-Assisted Laser Desorption Ionization-Time of Flight Mass Spectrometry. J Clin Microbiol. 53, 2355-8. 

Parkins MD, Floto RA. (2015) Emerging bacterial pathogens and changing concepts of bacterial pathogenesis in cystic fibrosis. J Cyst Fibros. 14, 293-304. 

Floto RA, Haworth CS. The growing threat of nontuberculous mycobacteria in CF. (2015) J Cyst Fibros. 14, 1-2.

Hepburn L, Prajsnar TK, Klapholz C, Moreno P, Loynes CA, Ogryzko NV, Brown K, Schiebler M, Hegyi K, Antrobus R, Hammond KL, Connolly J, Ochoa B, Bryant C, Otto M, Surewaard B, Seneviratne SJ, Grogono DM, Cachat J, Ny T, Kaser A, Török ME, Peacock SJ, Holden M, Blundell T, Wang L, Ligoxygakis P, Minichiello L, Woods CG, Foster SJ, Renshaw SA, Floto RA (2014). A Spaetzle-like role for Nerve Growth Factor - in vertebrate immunity to Staphylococcus aureus. Science 346, 641-646.

Schiebler M, Brown K, Hegyi K, Newton SM, Renna M, Hepburn L, Schaffner C, Coulter S, Obregón A, Henao Tamayo M, Basaraba R, Ordway DJ Kampmann B, Anderson KE, Hawkins PT, Rubinsztein DC, Floto RA (2014). Anticonvulsants stimulate mTOR-independent autophagic killing of Mycobacterium tuberculosis through inositol depletion.  EMBO Molecular Medicine 7, 127-139.

Bryant JM, Grogono DM, Greaves D, Foweraker J, Roddick I, Inns T, Reacher M, Haworth CS, Curran MD, Harris SR, Peacock SJ, Parkhill J, Floto RA (2013). Whole-genome sequencing to identify transmission of Mycobacterium abscessus between patients with cystic fibrosis: a retrospective cohort study. Lancet.  381: 1551-60. PMC3664974

Stout JE, Floto RA (2012) Treatment of Mycobacterium abscessus: all macrolides are equal but perhaps some are more equal than others. Am J Respir Crit Care Med 186: 822-3.

Renna M, Schaffner C, Brown K, Shang S, Tamayo MH, Hegyi K, Grimsey NJ, Cusens D, Coulter S, Cooper J, Bowden AR, Newton SM, Kampmann B, Helm J, Jones A, Haworth CS, Basaraba RJ, DeGroote MA, Ordway DJ, Rubinsztein DC, Floto RA. (2011). Azithromycin blocks autophagy and may predispose cystic fibrosis patients to mycobacterial infection. J Clin Invest. 121, 3554-63.

Williams A, Sarkar S, Cuddon P, Ttofi EK, Saiki S, Siddiqi FH, Jahreiss L, Fleming A, Pask D, Goldsmith P, O'Kane CJ, Floto RA & Rubinsztein DC. (2008). Novel targets for Huntington's disease in an mTOR-independent autophagy pathway. Nat Chem Biol. 4, 295-305.

Floto, R.A., Sarkar, S, Perlstein, E.O., Kampmann, B., Schreiber, S.L. & Rubinsztein, D.C. (2007). Small molecule enhancers of rapamycin-induced TOR inhibition promote autophagy, reduce toxicity in Huntington’s disease models and enhance killing of mycobacteria by macrophages. Autophagy 3, 620-622.

Clatworthy, M.R., Willcocks, L., Urban, B.,Langhorne, J., Williams, T., Watkins, N.A., Rankin, A., Floto, R.A. & Smith, K.G.C. (2007). SLE-associated defects in the inhibitory receptor Fc RIIb reduce susceptibility to malaria. Proc Natl Acad Sci U S A. 104, 7169-7174.

Floto, R.A., MacAry, P.A., Boname, J.M., Mien, T.S., Houben, E.N.G., Pieters, J., Day, C., Oehlmann, W., Singh, M., Smith, K.G.C. & Lehner, P.J. (2006). Dendritic cell stimulation by mycobacterial HSP70 is mediated through the HIV co-receptor CCR5. Science 314, 454-458.

Floto, R.A., Clatworthy, M.R., Heilbronn, K.R., Rosner, D.R., MacAry, P.A., Rankin, A., Lehner, P.J., Ouwehand, W.H., Allen, J.M., Watkins, N.A. & Smith, K.G.C (2005). An SLE-associated polymorphism of the inhibitory receptor FcRIIb excludes it from lipid rafts and leads to loss of function. Nature Medicine, 11, 1056-1058. Corresponding author.